Can testosterone increase blood pressure? A practical guide to TRT and blood pressure for men

Yes, testosterone can increase blood pressure in some men, but the average effect is usually small and the research is mixed. The bigger issue is identifying who is most likely to see a rise, then monitoring blood pressure and lab markers so treatment stays safe.

Key takeaways

• Studies of testosterone therapy and blood pressure do not agree. A 2024 registry study in World Journal of Men’s Health linked testosterone undecanoate treatment to lower blood pressure in men with testosterone deficiency,^[1] while other studies have found small increases.^[2]
• In a 2021 study of oral testosterone undecanoate in the Journal of Clinical Hypertension, 24 hour ambulatory systolic blood pressure rose by about 2 mmHg on average, with larger rises in men already taking blood pressure medication.^[2] Hemoglobin levels were not related to the change.^[2]
• Testosterone deficiency is diagnosed only when persistent symptoms are present and low morning testosterone is confirmed on repeat testing. According to the Endocrine Society’s 2018 guideline, the cause of the deficiency should then be evaluated.^[3] Measuring LH and FSH alongside testosterone separates primary from secondary hypogonadism, which changes the choice of treatment.
• Home monitoring is most useful when you sit quietly for 5 minutes, keep both feet on the floor, take 2 readings one minute apart, and log results daily.
• Lifestyle targets that support blood pressure include 150 minutes per week of moderate activity, at least 7 hours of sleep, and whole food eating patterns such as DASH or Mediterranean style diets.

The relationship between testosterone and blood pressure in men

Testosterone therapy can raise blood pressure in some men. The average rise in studies has been small, and it does not mean every man on treatment will develop hypertension. Product labels for several testosterone preparations caution that treatment may be associated with hypertension.^[1]

The evidence points in both directions. According to a 2024 analysis in World Journal of Men’s Health of a registry of 737 men with testosterone deficiency, men treated with testosterone undecanoate had lower systolic and diastolic blood pressure over follow-up, while blood pressure rose in men who were not treated.^[1] Among treated men who never took blood pressure medication, the median systolic drop was 12.5 mmHg.^[1] The registry is observational, so it shows an association, not proof that testosterone lowered blood pressure. A 2021 study of 155 men taking an oral testosterone undecanoate (Kyzatrex) found small increases instead.^[2] Average 24 hour ambulatory systolic pressure rose by 1.7 to 1.8 mmHg at 120 and 180 days.^[2] Results differ across testosterone formulations and patient groups. For that reason, clinicians treat blood pressure as an individualized risk question rather than a universal side effect.

The wider picture matters too. A 2010 review in Therapeutic Advances in Endocrinology and Metabolism describes how low testosterone in men is linked with obesity, insulin resistance, metabolic syndrome, and type 2 diabetes.^[4] The same review notes that low testosterone and metabolic syndrome are each independently associated with higher cardiovascular mortality.^[4] At the time, no long term trials had tested whether testosterone replacement changes mortality.^[4] The TRAVERSE trial, published in 2023 in the New England Journal of Medicine, randomized 5,246 men aged 45 to 80 with symptoms of hypogonadism and existing or high cardiovascular risk.^[5] Over a mean follow-up of 33 months, testosterone gel was noninferior to placebo for major adverse cardiac events, while atrial fibrillation, acute kidney injury, and pulmonary embolism were more frequent with testosterone.^[5] Avoiding treatment does not remove cardiovascular risk, and in a man with confirmed deficiency it may leave one risk factor unmanaged.

How testosterone therapy can shift blood pressure

Red blood cells, hematocrit, and thicker blood

Testosterone stimulates red blood cell production. Hematocrit is the percent of your blood made up of red blood cells. A 2018 review in Sexual Medicine Reviews found that erythrocytosis, an abnormally high red blood cell concentration, is a well established risk of testosterone therapy.^[6] Its incidence is highest on short acting injectable formulations.^[6]

Very high hematocrit makes blood more viscous, meaning thicker and slower flowing. The same review notes that higher viscosity may raise the risk of complications in the heart, brain, and peripheral circulation, although evidence linking testosterone therapy itself to those complications is limited.^[6] Whether thicker blood raises blood pressure in men on testosterone is less clear. In the 2021 oral testosterone undecanoate study, hemoglobin levels were not related to changes in ambulatory blood pressure.^[2] Hematocrit remains one of the most practical safety markers clinicians track during treatment.

Fluid retention and higher blood volume

Fluid retention is a possible side effect of testosterone therapy. Retaining fluid raises blood volume, which increases pressure on vessel walls and can raise blood pressure. The effect matters most in men whose baseline pressure is already high.

Clinicians therefore take sudden weight gain or new swelling seriously early in therapy or after a dose change. Fluid shifts are not always dangerous, but they are a reason to reassess.

Blood vessel tone, dilation, and flow

Testosterone also acts on the cardiovascular system, including blood vessel dilation and blood flow. Vasodilation is the widening of blood vessels, which lowers resistance to flow and supports healthier blood pressure. These effects vary with dose, formulation, and a man’s underlying vascular health. That variation is one reason different studies reach different blood pressure findings.

Kidney support, salt balance, and who is at higher risk

Androgens also act on the kidneys, which regulate the body’s salt and water balance, a major driver of blood pressure. This does not make testosterone therapy a blood pressure medication, but it does affect a system that controls blood pressure.

Starting blood pressure and existing treatment appear to shape the response. In the 2021 oral testosterone undecanoate study, baseline ambulatory blood pressure and use of blood pressure medication were the factors correlated with change, while testosterone levels and hemoglobin were not.^[2] In the 2024 registry, men with higher starting blood pressure had larger reductions, while hematocrit and waist circumference were not associated with the change.^[1] Group averages cannot predict how one man will respond. Measuring his own blood pressure can show it.

Conditions that change your risk on TRT

These conditions can shift a man’s risk because they change baseline blood pressure, fluid balance, or how the body responds to testosterone.

• Central obesity: Fat gain around the abdomen is strongly linked to metabolic risk in men and is associated with low testosterone in observational data.^[4]
• Metabolic syndrome: A cluster of risk factors that raises cardiovascular risk, including abdominal obesity and impaired glucose metabolism. It commonly occurs together with low testosterone in men.^[4]
• Type 2 diabetes: A metabolic disease linked with higher cardiovascular risk. Hypogonadism is common in men with type 2 diabetes.^[4]
• Hypertension already treated with medication: In the 2021 oral testosterone undecanoate study, men on blood pressure medication had larger increases in 24 hour systolic pressure than men not taking it (3.4 vs 0.7 mmHg at 120 days).^[2] The 2024 registry found larger reductions in men on blood pressure medication.^[1] This group needs closer monitoring rather than a fixed expectation.
• High or rising hematocrit: Erythrocytosis is a well established risk of testosterone therapy.^[6] A man who starts with a high hematocrit has less margin before it reaches a level that calls for a dose change.

The evidence is mixed because studies differ by testosterone formulation, dose, trial design, and patient population. Observational studies can show association but cannot prove cause. Randomized trials are stronger, but they may not reflect every real world patient, especially men with multiple comorbidities.

Symptoms and signals to watch while on TRT

Blood pressure changes are often silent, so measured numbers are more reliable than how you feel. Men on testosterone therapy should still watch for patterns that can point to fluid retention, rising hematocrit, or loss of blood pressure control.

• Home blood pressure trend drifting upward: In the 2021 ambulatory monitoring study, average 24 hour systolic pressure rose by about 2 mmHg, a change that does not by itself mean hypertension.^[2] A sustained trend across many readings matters more than any single reading.
• New swelling in ankles or lower legs: This can signal fluid retention, especially if it shows up after starting or increasing a dose.
• Rapid, unexplained scale weight gain: This may point to water retention rather than fat gain.
• Lab report shows rising hematocrit: Hematocrit is a tracked safety marker on testosterone therapy because erythrocytosis is a well established effect of treatment.^[6]
• Existing hypertension getting harder to control: If your usual plan stops working, review your testosterone protocol and overall cardiovascular strategy with a clinician.

What to do about it

Plan for monitoring from the first day of treatment. That includes confirming clinically meaningful testosterone deficiency, choosing a therapy that fits your diagnosis and goals, and tracking blood pressure and hematocrit.

According to the Endocrine Society’s 2018 clinical practice guideline, men on testosterone therapy should be monitored on a standardized plan that includes symptoms, adverse effects, testosterone levels, and hematocrit.^[3] The guideline also advises against starting therapy in men with elevated hematocrit.^[3] Blood pressure, lipids, and overall cardiovascular risk belong in the same review.

1. Step 1: Confirm the diagnosis and your baseline risk: Get repeat morning total testosterone testing on separate days and a full hypogonadism workup before treatment. Luteinizing hormone (LH) is a pituitary signal that tells the testes to produce testosterone. LH and follicle stimulating hormone (FSH) separate primary hypogonadism from secondary hypogonadism. Primary hypogonadism is testicular failure, usually with high LH and FSH. Secondary hypogonadism has pituitary or hypothalamic causes, with low or inappropriately normal LH and FSH. The Endocrine Society guideline recommends confirming low testosterone with a repeat morning measurement.^[3] It recommends free testosterone by equilibrium dialysis or an accurate formula when total testosterone is borderline or SHBG may be abnormal, and evaluation of the cause of the deficiency.^[3] The pattern shapes treatment. In secondary or functional hypogonadism the testes still work, so treatments that restart the body’s own production are an option. One of them is enclomiphene. A 2014 randomized phase II trial in Fertility and Sterility of men with secondary hypogonadism found that enclomiphene raised morning testosterone to levels similar to topical testosterone gel, increased LH and FSH, and conserved sperm counts.^[7] The Endocrine Society guideline recommends against starting testosterone therapy in men planning fertility in the near term,^[3] so it should be avoided in men actively seeking fertility. Ask your clinician about baseline labs, including a CBC with hematocrit and metabolic and lipid markers, so decisions rest on overall risk rather than a single testosterone number.
2. Step 2: Build a blood pressure friendly foundation before and during treatment: Manage high blood pressure before starting testosterone therapy when possible, and use lifestyle levers that reliably reduce blood pressure. Aim for 150 minutes per week of moderate intensity aerobic activity such as brisk walking, swimming, biking, dancing, or jogging. Seventy-five minutes per week of higher intensity training is an alternative. Prioritize whole foods with DASH or Mediterranean style patterns that limit high sodium foods. Target at least 7 hours of sleep nightly, because chronic short sleep is linked to higher blood pressure in men. If stress is high, use practical stress reduction such as scheduling, mindfulness, and reducing avoidable triggers. Over time, stress hormones can increase heart rate and constrict blood vessels.
3. Step 3: Monitor as part of the prescription: Use an upper arm cuff monitor at home, since cuff devices are typically more accurate than wrist devices. Measure at the same time each day. Sit upright with feet on the floor and your arm supported. Rest for 5 minutes. Take 2 readings one minute apart. Log results so you and your clinician can spot trends. Pair blood pressure tracking with lab monitoring, especially hematocrit, since erythrocytosis is a well established side effect of testosterone therapy.^[6] If you use a local clinic or telehealth service, make sure it includes ongoing follow up, clear lab monitoring intervals, and dose adjustments based on symptoms and safety markers.

Veedma offers testing that includes total and free testosterone measured by LC-MS/MS with LH and FSH, or a review of labs you already have, with care from licensed providers. In Veedma’s protocol, enclomiphene or the enclomiphene plus tadalafil tablet may be prescribed when symptoms persist, free testosterone is below 100 pg/mL, and LH is below 8 mIU/mL. Enclomiphene is not an FDA-approved drug; it is prescribed after a provider confirms the diagnosis and is compounded by a licensed U.S. pharmacy.

Myth vs fact

Myth: “TRT always causes high blood pressure.”

Fact: Studies are mixed. Some show small increases, others show no link, and a 2024 registry of 737 men with testosterone deficiency found lower blood pressure in men treated with testosterone undecanoate.^[1]

Myth: “If my systolic number goes up a few points, I have hypertension.”

Fact: A small rise is not the same as developing hypertension. In the 2021 ambulatory monitoring study, average 24 hour systolic pressure rose by less than 2 mmHg.^[2] Trends over time and your overall risk profile matter more than one reading.

Myth: “If I feel fine, my blood pressure is fine.”

Fact: Blood pressure changes are often silent. Home monitoring is more reliable than symptoms.

Myth: “High hematocrit is just a lab quirk.”

Fact: Erythrocytosis is a well established effect of testosterone therapy. Thicker blood may raise the risk of vascular complications, although direct evidence of that link is limited.^[6] Hematocrit is a core safety marker for men on therapy.

Myth: “The only option is injections forever.”

Fact: Treatment depends on whether hypogonadism is primary or secondary. Men with secondary or functional hypogonadism have working testes. They may be candidates for treatments that raise the body’s own testosterone, such as enclomiphene. Testosterone therapy should be avoided in men actively seeking fertility.

Bottom line

Testosterone therapy and blood pressure have a real connection, but the effect is not the same in every man. Some studies show small increases and others show no change or reductions. Men who already have hypertension or develop rising hematocrit during therapy need closer attention. If you are considering testosterone therapy, confirm a true deficiency, choose a therapy that fits your diagnosis and goals, and monitor blood pressure and hematocrit consistently with a clinician.

References

1. Hackett G, Mann A, Haider A, et al. Testosterone Replacement Therapy: Effects on Blood Pressure in Hypogonadal Men. World J Mens Health. 2024;42:749-761. PMID: 38449452
2. White WB, Bernstein JS, Rittmaster R, et al. Effects of the oral testosterone undecanoate Kyzatrex™ on ambulatory blood pressure in hypogonadal men. J Clin Hypertens (Greenwich). 2021;23:1420-1430. PMID: 34114726
3. Bhasin S, Brito JP, Cunningham GR, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103:1715-1744. PMID: 29562364
4. Muraleedharan V, Jones TH. Testosterone and the metabolic syndrome. Ther Adv Endocrinol Metab. 2010;1:207-23. PMID: 23148165
5. Lincoff AM, Bhasin S, Flevaris P, et al. Cardiovascular Safety of Testosterone-Replacement Therapy. N Engl J Med. 2023;389:107-117. PMID: 37326322
6. Ohlander SJ, Varghese B, Pastuszak AW. Erythrocytosis Following Testosterone Therapy. Sex Med Rev. 2018;6:77-85. PMID: 28526632
7. Wiehle RD, Fontenot GK, Wike J, et al. Enclomiphene citrate stimulates testosterone production while preventing oligospermia: a randomized phase II clinical trial comparing topical testosterone. Fertil Steril. 2014;102:720-7. PMID: 25044085